AstraZeneca trumpets solo strength in cancer drugs post Pfizer struggle
By Ben Hirschler and Simon Jessop LONDON (Reuters) – AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs at an investor day on Tuesday, aiming to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May. The company also brought forward the filing date for a new lung cancer pill, and said it could win between eight and 10 new approvals in 2015-2016 for drugs dealing with a wide range of diseases. …
